Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.

Leukemia & lymphoma - 1 Jan 2023

Amaador Karima, Kersten Marie J, Minnema Monique C, Vos Josephine M I

Abstract excerpt

Waldenström's Macroglobulinemia (WM) is a rare type of indolent non-Hodgkin lymphoma (NHL) that remains incurable. Several effective agents such as monoclonal antibodies (in combination with chemotherapy), Bruton's tyrosine kinase inhibitors, proteasome inhibitors, and BCL2 inhibitors are (becoming) available for the treatment of relapsed and refractory WM. There is however no consensus on a preferred treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents
Share to Lymphoma, Non-Hodgkin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloid Differentiation Factor 88

Share to Waldenstrom Macroglobulinemia

Source

Identifiers

PMID: 36282673
DOI: 10.1080/10428194.2022.2131423

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.PMID 36282673Read ↗

Advances in Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Emerging drugs for the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

Current approach to Waldenström macroglobulinemia.Semantic proximity Read ↗

Toward personalized treatment in Waldenström macroglobulinemia.Semantic proximity Read ↗

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.Semantic proximity Read ↗

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Semantic proximity Read ↗

Current approach to Waldenström Macroglobulinemia.Semantic proximity Read ↗

How we manage patients with Waldenström macroglobulinaemia.Semantic proximity Read ↗

Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.Semantic proximity Read ↗

How to Sequence Therapies in Waldenström Macroglobulinemia.Semantic proximity Read ↗

Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenströms Macroglobulinemia- a single center real world retrospective analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.